Home › Non-Small Cell Lung Cancer › Illinois › Waukegan
Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa Waukegan, IL
16 pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Waukegan (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Nagre-recruitPhase 3
- AMG Libertyville - Oncology, Libertyville · 8 mi ang layo
- Condell Memorial Hospital, Libertyville · 8 mi ang layo
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Nagre-recruitPhase 3
- Northwestern Medicine Lake Forest Hospital, Lake Forest · 7 mi ang layo
- Northwestern Medicine Grayslake Outpatient Center, Grayslake · 10 mi ang layo
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2
- City of Hope Chicago, Zion · 6 mi ang layo
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Nagre-recruitPhase 3
- Advocate Medical Group - Libertyville Oncology, Libertyville · 8 mi ang layo
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Captain James A. Lovell Federal Health Care Center, North Chicago · 3 mi ang layo
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- City of Hope® Cancer Center Chicago, Zion · 6 mi ang layo
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Nagre-recruitPhase 3
- Research Site, Zion · 6 mi ang layo
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- Research Site, North Chicago · 3 mi ang layo
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Nagre-recruitPhase 3
- Northwestern Medicine Lake Forest Hospital, Lake Forest · 7 mi ang layo
- Northwestern Medicine Grayslake Outpatient Center, Grayslake · 10 mi ang layo
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Nagre-recruitPhase 3
- Cancer Treatment Centers of America (CTCA), Zion · 6 mi ang layo
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Northwestern Medicine Lake Forest Hospital, Lake Forest · 7 mi ang layo
- AMG Libertyville - Oncology, Libertyville · 8 mi ang layo
- Condell Memorial Hospital, Libertyville · 8 mi ang layo
- at 1 pa
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Northwestern Medicine Lake Forest Hospital, Lake Forest · 7 mi ang layo
- AMG Libertyville - Oncology, Libertyville · 8 mi ang layo
- Condell Memorial Hospital, Libertyville · 8 mi ang layo
- at 1 pa
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2/3
- Northwestern Medicine Lake Forest Hospital, Lake Forest · 7 mi ang layo
- AMG Libertyville - Oncology, Libertyville · 8 mi ang layo
- Condell Memorial Hospital, Libertyville · 8 mi ang layo
- at 1 pa
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Northwestern Medicine Lake Forest Hospital, Lake Forest · 7 mi ang layo
- Northwestern Medicine Grayslake Outpatient Center, Grayslake · 10 mi ang layo
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
Nagre-recruitPhase 2
- City of Hope at Chicago, Zion · 6 mi ang layo
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Nagre-recruitObservasyonal na pag-aaral
- AMG Libertyville - Oncology, Libertyville · 8 mi ang layo
- Condell Memorial Hospital, Libertyville · 8 mi ang layo
Pag-aaral para sa Non-Small Cell Lung Cancer sa ibang lungsod
- Houston, TX145 pag-aaral
- New York City, NY121 pag-aaral
- Arlington, VA104 pag-aaral
- Nashville, TN97 pag-aaral
- Boston, MA90 pag-aaral
- Los Angeles, CA87 pag-aaral
- St. Louis, MO73 pag-aaral
- Chicago, IL61 pag-aaral
- Baltimore, MD60 pag-aaral
- San Antonio, TX59 pag-aaral
- Columbus, OH57 pag-aaral
- Washington, DC55 pag-aaral
Iba pang pag-aaral sa Waukegan
- Kanser sa Baga16 pag-aaral
- Kanser sa Suso12 pag-aaral
- Ulcerative Colitis7 pag-aaral
- Kanser sa Bato (Renal Cell Carcinoma)7 pag-aaral
- Kanser sa Ovary6 pag-aaral
- Metastatic Cancer6 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg6 pag-aaral
- Colorectal Cancer6 pag-aaral
- Kanser sa Prostate6 pag-aaral
- Melanoma5 pag-aaral
- Acute Myeloid Leukemia5 pag-aaral
- Crohn's Disease5 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.